A powerful approach
We are leveraging the principle of synthetic lethality to develop therapies that take aim at drivers of cancer that have not been approached before.
At Tango, we have built a high-throughput, robust target discovery platform that uses CRISPR to find vulnerabilities in specific types of cancer cells. Our process is efficient and highly productive; we can complete ~20 target discovery screens and validate six to eight novel targets a year at a steady state.
Target Discovery Pipeline
Once we have validated the targets, we deploy proven approaches in efficient ways to discover and develop new drugs. We are moving steadily toward the clinic in cancers with high unmet need.
Drug Discovery Pipeline
We aim to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. We believe strategic collaborations with pharma and other biotech companies can help us achieve this goal and deliver more novel cancer drug targets and medicines to patients. Please reach out if you are interested in exploring ways to work together: firstname.lastname@example.org.